Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rafael Rosell

Showing results (231-240 of 470) with videos related to

Pageof 47
Sort By:
Plos One|May 19, 2016
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase ExpressionAndrés Felipe Cardona, Leonardo Rojas, Beatriz Wills, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2018
Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer CellsJordi Codony-Servat, Silvia García-Roman, Miguel Ángel Molina-Vila, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2021
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysisPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.
Nature|March 25, 2011
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFRTrever G Bivona, Haley Hieronymus, Joel Parker, et al.
Anticancer Research|January 12, 2007
Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancerCarlos Camps, Rafael Sirera, Roy M Bremnes, et al.
The Oncologist|February 7, 2015
The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trialsYoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, et al.
Translational Lung Cancer Research|September 21, 2020
CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancerAndrea Moreno-Manuel, Eloisa Jantus-Lewintre, Ines Simões, et al.
JTO Clinical and Research Reports|September 30, 2021
BRCA1 Expression and Outcome in Patients With <i>EGFR</i>-Mutant NSCLC Treated With Gefitinib Alone or in Combination With OlaparibNiki Karachaliou, Oscar Arrieta, Ana Giménez-Capitán, et al.
Translational Lung Cancer Research|March 26, 2015
ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutationNiki Karachaliou, Ana Gimenez-Capitan, Ana Drozdowskyj, et al.
Cancers|June 11, 2020
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 AntibodiesMariacarmela Santarpia, Andrés Aguilar, Imane Chaib, et al.
Pageof 47

Showing results (231-240 of 470) with videos related to

Sort By:
Pageof 47
Plos One|May 19, 2016
Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase ExpressionAndrés Felipe Cardona, Leonardo Rojas, Beatriz Wills, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 12, 2018
Anti-Epidermal Growth Factor Vaccine Antibodies Enhance the Efficacy of Tyrosine Kinase Inhibitors and Delay the Emergence of Resistance in EGFR Mutant Lung Cancer CellsJordi Codony-Servat, Silvia García-Roman, Miguel Ángel Molina-Vila, et al.
Lung Cancer (Amsterdam, Netherlands)|March 1, 2021
Clinical utility of plasma EGFR mutation detection with quantitative PCR in advanced lung cancer: A meta-analysisPeey-Sei Kok, Kirsty Lee, Sally Lord, et al.
Nature|March 25, 2011
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFRTrever G Bivona, Haley Hieronymus, Joel Parker, et al.
Anticancer Research|January 12, 2007
Quantification in the serum of the catalytic fraction of reverse telomerase: a useful prognostic factor in advanced non-small cell lung cancerCarlos Camps, Rafael Sirera, Roy M Bremnes, et al.
The Oncologist|February 7, 2015
The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trialsYoshikazu Hasegawa, Masahiko Ando, Makoto Maemondo, et al.
Translational Lung Cancer Research|September 21, 2020
CD5 and CD6 as immunoregulatory biomarkers in non-small cell lung cancerAndrea Moreno-Manuel, Eloisa Jantus-Lewintre, Ines Simões, et al.
JTO Clinical and Research Reports|September 30, 2021
BRCA1 Expression and Outcome in Patients With <i>EGFR</i>-Mutant NSCLC Treated With Gefitinib Alone or in Combination With OlaparibNiki Karachaliou, Oscar Arrieta, Ana Giménez-Capitán, et al.
Translational Lung Cancer Research|March 26, 2015
ROR1 as a novel therapeutic target for EGFR-mutant non-small-cell lung cancer patients with the EGFR T790M mutationNiki Karachaliou, Ana Gimenez-Capitan, Ana Drozdowskyj, et al.
Cancers|June 11, 2020
Non-Small-Cell Lung Cancer Signaling Pathways, Metabolism, and PD-1/PD-L1 AntibodiesMariacarmela Santarpia, Andrés Aguilar, Imane Chaib, et al.
Pageof 47